Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate FDA reform bill floor debate to continue week of Sept. 8.

This article was originally published in The Tan Sheet

Executive Summary

NATIONAL UNIFORMITY FOR OTCs, COSMETICS MAY PROMPT FDA REFORM VETO recommendation by HHS Secretary Donna Shalala, according to a Sept. 5 letter from the HHS secretary to Senate Labor & Human Resources Committee Chairman James Jeffords (R-Vt.). "The administration has serious concerns about far-reaching preemption -- particularly in the absence of a strong federal program," Shalala writes. Referring to the provision in Jeffords' FDA Modernization & Accountability Act (S 830) that gives FDA federal preemption authority over state safety and labeling regs for OTC drugs and cosmetics, Shalala states "if the bill were maintained in its present form...I would be forced to recommend to the President that he veto this legislation."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087513

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel